Rosen Law Firm has initiated a securities class action lawsuit against Inovio Pharmaceuticals Inc. (NASDAQ: INO), alleging the company made materially false and misleading statements to investors during a period spanning from October 10, 2023, through December 26, 2025. The litigation contends that Inovio failed to adequately disclose manufacturing deficiencies affecting its CELLECTRA device technology, a key component of the company's vaccine delivery platform.
The complaint further alleges that Inovio overstated the regulatory prospects for its INO-3107 drug candidate and misrepresented its ability to meet previously announced FDA submission timelines. According to the lawsuit, the company did not timely inform investors that the projected regulatory pathway was unlikely to be achieved as originally communicated. These allegations form the basis of claims that investors suffered damages as a result of purchasing securities at artificially inflated prices.
Investors who purchased Inovio securities during the class period have until April 7, 2026, to submit a lead plaintiff application. Legal counsel specializing in securities litigation recommends that affected shareholders act promptly to preserve their rights and understand the potential implications of the ongoing litigation.